I'm not aware of the details of the licensing agreement between Provista/Memory Dx and University of Leipzig, but I can provide details of Amarantus' agreements with Memory Dx.
On Oct. 11, 2012 Amarantus announced an option to license LymPro from Memory Dx.
http://ir.stockpr.com/amarantus/company-news/...blood-test
On Dec. 14, 2012 Amarantus announced the licensing of LymPro from Memory Dx.
http://ir.stockpr.com/amarantus/company-news/...blood-test
The following excerpt is from the 8-K/A submitted on Dec. 14, 2012:
On May 5, 2014 Amarantus announced licensing of Version 2 of LymPro from Memory Dx.
http://ir.stockpr.com/amarantus/company-news/...-memory-dx
The following excerpts are from the 8-K submitted on May 5, 2014:
On Oct. 11, 2012 Amarantus announced an option to license LymPro from Memory Dx.
http://ir.stockpr.com/amarantus/company-news/...blood-test
On Dec. 14, 2012 Amarantus announced the licensing of LymPro from Memory Dx.
http://ir.stockpr.com/amarantus/company-news/...blood-test
The following excerpt is from the 8-K/A submitted on Dec. 14, 2012:
http://www.sec.gov/Archives/edgar/data/142481...16_8ka.htmQuote:Pursuant to the terms of the License Agreement, Registrant will issue 2,000,000 shares of its common stock to MDx and will provide MDx with a royalty equal to 9% of the net proceeds of all sales resulting from the License . Further, MDx and Registrant agreed to complete a validation study regarding a blood test for the detection of Alzheimer’s disease. To prepare the laboratory for this study, Registrant shall pay to MDx $15,000 upon the execution of the License Agreement, an additional $15,000 within 30 days following the execution of the License Agreement, and $20,000 within 60 days following the execution of the License Agreement. Registrant will also assist MDx in its fund raising strategy, and, upon successful completion of the validation study, provide MDx $1,000,000, payable in cash or Company’s stock, as defined in the License Agreement. The Company may sell, sub-license or assign the License Agreement and has an option to terminate the License Agreement upon 30 days written notice if MDx is unable to meet its obligations regarding the validation study.
On May 5, 2014 Amarantus announced licensing of Version 2 of LymPro from Memory Dx.
http://ir.stockpr.com/amarantus/company-news/...-memory-dx
The following excerpts are from the 8-K submitted on May 5, 2014:
http://www.sec.gov/Archives/edgar/data/142481...310_8k.htmQuote:Memory Dx, LLC Transaction
On April 29, 2014, Amarantus Bioscience Holdings, Inc., a Nevada corporation (the “Company”) entered into an asset purchase agreement (the “MDx APA”) with Memory Dx, LLC, an Arizona limited liability company (“MDx”) pursuant to which the Company purchased all of the assets of MDx, including all right, title and interest in the LymPro Technology (as defined in the MDx APA). Such assets include all intellectual property, goodwill, patents and all copyrights owned by MDx (altogether, the “Assets”), subject to certain exclusions and further described in the APA.
As consideration for transfer of the Assets pursuant to the MDx APA, the Company shall pay to Mdx
(i) $50,000 upon execution of the MDx APA,
(ii) $50,000 upon the date 60 days after execution of the MDx APA, and
(iii) $50,000 on the date 120 days after execution of the MDx APA.
Additionally, the Company shall issue to MDx upon delivery of the Assets, 1,500,000 shares of the Company’s common stock and shall provide MDx with piggy-back registration rights as it related to such shares.
Contingent upon
(i) the Company entering into a direct licensing agreement with the University of Leipzig (“Leipzig”) pursuant to which Leipzig would grant the Company a direct license to certain assets now licensed to MDx by Leipzig, and
(ii) MDx terminating the license agreement it currently holds with Leipzig as it relates to such licensed assets with the Company’s prior written consent, the Company shall issue to MDx, upon the date 10 days after the execution of a direct license agreement between the Company and Leipzig, 6,500,000 shares of the Company’s common stock and shall provide MDx with piggy-back registration rights as it related to such shares.
Provista Diagnostics, Inc. Transaction
On May 1, 2014, the Company entered into an asset purchase agreement (the “Provista APA”) with Provista Diagnostics, Inc., a Delaware Corporation (“Provista”) pursuant to which the Company purchased certain assets of Provista related to a fluorescently activated cell sorter (“FACS”), including all right, title and interest in the certain assets, equipment, software and technology related to FACS (altogether, the “Assets”).
As consideration for transfer of the Assets pursuant to the Provista APA, the Company shall, upon closing of the Provista APA, pay to Provista a one-time cash payment of $20,000 .
